A cancer drug shows promise, at a price that many can't pay.

By ALEX BERENSON Published: February 15, 2006 Doctors are excited about the prospect of Avastin, a drug already widely used for colon cancer, as a crucial new treatment for breast and lung cancer, too. But doctors are cringing at the price the maker, Genentech, plans to charge for it: about $100,000 a year. That price, about double the current level as a colon cancer treatment, would raise Avastin to an annual cost typically found only for